1227675-52-6

Usage

Uses

Used in Pharmaceutical Research:
(R)-α-Methylamino-2,3-dihydro-4-methoxy-7-nitro-γ-oxo-1H-indole-1-butanoic acid is used as a ligand for glutamate receptor subtypes. Its application in this field is crucial for the isolation and study of post-synaptic receptor activation, which is a key process in the transmission of nerve impulses and communication between neurons. Understanding the role of MNI-caged-NMDA in receptor activation can lead to the development of new therapeutic strategies for neurological disorders and conditions related to glutamate receptor dysfunction.
Used in Neuroscience Research:
In the field of neuroscience, (R)-α-Methylamino-2,3-dihydro-4-methoxy-7-nitro-γ-oxo-1H-indole-1-butanoic acid serves as a valuable tool for investigating the complex interactions between neurons and their receptors. By acting as a ligand for glutamate receptor subtypes, MNI-caged-NMDA can help researchers gain insights into the molecular mechanisms underlying synaptic transmission and neuronal communication. This knowledge can be instrumental in the development of novel treatments for neurological conditions, such as epilepsy, Alzheimer's disease, and other cognitive disorders.
Used in Drug Development:
The unique properties of (R)-α-Methylamino-2,3-dihydro-4-methoxy-7-nitro-γ-oxo-1H-indole-1-butanoic acid make it a promising candidate for the development of new drugs targeting glutamate receptor subtypes. By modulating the activity of these receptors, MNI-caged-NMDA could potentially be used to treat a range of neurological and psychiatric disorders, including anxiety, depression, and addiction. Furthermore, its ability to influence post-synaptic receptor activation may also make it a valuable asset in the development of drugs aimed at improving cognitive function and memory.